The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.
Frederik Marme
No relevant relationships to disclose
Justo Lorenzo Bermejo
No relevant relationships to disclose
Hans-Peter Sinn
No relevant relationships to disclose
Peter Lichter
Research Funding - breast cancer
Florian Schuetz
No relevant relationships to disclose
Joachim Rom
No relevant relationships to disclose
Julia Aigner
No relevant relationships to disclose
Christof Sohn
No relevant relationships to disclose
Andreas Schneeweiss
Honoraria - breast cancer
Research Funding - breas cancer
Other Remuneration - breast cancer